In September 2017, MAPS raised nearly $545,000 in new donations and pledges from 308 supporters. As Burning Man 2017 came to a close, so too did our Zendo Project fundraising. We raised over $102,000 for the Zendo Project, far exceeding our initial $60,000 goal. With these funds, we are able to completely fund Zendo Project’s services at Burning Man 2017 as well as support Zendo’s activities throughout the year.
MAPS is now shifting focus to raising funds for its Phase 3 studies of MDMA-assisted psychotherapy for PTSD. In August, MAPS was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). This encouraging news demonstrates the FDA’s support and desire to expeditiously make MDMA into a legal medicine. Phase 3 studies will cost between $25-$35 million for both FDA and European Medicines Agency (EMA) approval. With $15.5 million in hand or in multi-year pledges, there’s still a funding gap we need to close.
We extend a special thanks to those who so generously supported MAPS last month:
- Audra Foster ($8,500)
- James Stewart Campbell ($1,000)
- Lynne Farrow ($1,000)
- Andrew Ryan ($1,000)
- John Buchanan ($1,000)
MDMA/PTSD Phase 3 Studies
- Good Ventures ($500,000)
- Matthew Lessard ($4,100)
- Candra Docherty ($2,000)
- Sean Abraham ($1,000)
MDMA/PTSD Phase 2 Study in Boulder, CO
- Highfield Foundation ($2,500)
- Dale Okuno ($2,000)
- Tyler Norris ($1,000)
- Jeremy Tunnell ($1,000)
- Kirsty and Amir Nathoo ($1,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate